74 results
Page 3 of 4
8-K
EX-99.2
f4p3lwhl9rp
18 Mar 21
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
8:31am
8-K
EX-99.1
xccvy7ypxkk
5 Jan 21
Regulation FD Disclosure
8:30am
424B5
b7ih86g
28 Apr 20
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.1
x80d1
27 Apr 20
Regulation FD Disclosure
4:18pm
424B5
sbgu7ag
27 Apr 20
Prospectus supplement for primary offering
4:09pm
8-K
9eblxg735cg6
16 Apr 20
Entry into a Material Definitive Agreement
8:49am
424B5
mzknke20 sr8
16 Apr 20
Prospectus supplement for primary offering
8:44am
8-K
EX-99.2
qno4t3bv9vz
13 Jan 20
Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020
7:01am
8-K
EX-99.1
8f4h3sop2udld5r 72ht
13 Jan 20
Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020
7:01am
8-K
EX-99.1
5dkf7a0vwy ygqw
3 Dec 19
Regulation FD Disclosure
8:00am